Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Gastrointestinal Cancers Congress 2024

Is neo-adjuvant systemic treatment the standard of care for all non-metastatic gastric cancer patients?

Neo-adjuvant pro

Date

27 Jun 2024

Session

Is neo-adjuvant systemic treatment the standard of care for all non-metastatic gastric cancer patients?

Topics

Tumour Site

Oesophageal Cancer;  Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Salah-Eddin Al-Baltran

Authors

S. Al-Baltran

Author affiliations

  • IKF GmbH, Frankfurt/DE

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction and first vote

Presenter: Sara De Dosso

Session: Is neo-adjuvant systemic treatment the standard of care for all non-metastatic gastric cancer patients?

Resources:

Slides

Webcast

Adjuvant pro

Presenter: Sun Young Rha

Session: Is neo-adjuvant systemic treatment the standard of care for all non-metastatic gastric cancer patients?

Resources:

Slides

Webcast

Second vote and conclusions/discussion

Presenter: Sara De Dosso

Session: Is neo-adjuvant systemic treatment the standard of care for all non-metastatic gastric cancer patients?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.